Most people have never heard of primary biliary cholangitis (PBC), but the progressive, rare cholestatic liver disease can ...

Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that ...

Drug-induced liver injury including cholestasis is another form of acquired liver disease, accounting for approximately 2 to 5% of hospitalizations for jaundice, 10% of cases of hepatitis in all ...

People with liver disease often have high levels of bilirubin ... But, it can also result from a liver condition called intrahepatic cholestasis of pregnancy (ICP). With ICP, bile acids do ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

Cirrhosis progresses in stages, from a compensated phase with few symptoms to a decompensated phase with serious ...

GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver disease primary biliary cholangitis (PBC). Interim results from the ...

LIVMARLI Tablet formulation approved for patients with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic ...

When the stool is white or very light brown, this can signal a more serious problem, such as cholestasis, a type of liver disease. In newborns, cholestasis or any other problem with the liver ...

Mirum and Takeda entered into an exclusive license agreement in September 2021 for the development and commercialization of LIVMARLI for rare cholestatic pediatric liver diseases in Japan.